These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 11717419)

  • 1. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
    Kuritzkes DR
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
    [No Abstract]   [Full Text] [Related]  

  • 2. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
    Descamps D; Chaix ML; Montes B; Pakianather S; Charpentier C; Storto A; Barin F; Dos Santos G; Krivine A; Delaugerre C; Izopet J; Marcelin AG; Maillard A; Morand-Joubert L; Pallier C; Plantier JC; Tamalet C; Cottalorda J; Desbois D; Calvez V; Brun-Vezinet F; Masquelier B; Costagliola D;
    J Antimicrob Chemother; 2010 Dec; 65(12):2620-7. PubMed ID: 20965891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
    Kagan RM; Merigan TC; Winters MA; Heseltine PN
    Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
    [No Abstract]   [Full Text] [Related]  

  • 4. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
    Winters MA; Merigan TC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2575-82. PubMed ID: 15980322
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
    Flandre P; Descamps D; Joly V; Meiffrédy V; Tamalet C; Izopet J; Aboulker JP; Brun-Vézinet F
    Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
    Soriano V
    Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 9. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
    Garcia-Lerma JG; Nidtha S; Blumoff K; Weinstock H; Heneine W
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13907-12. PubMed ID: 11698656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant.
    Chetchotisakd P; Anunnatsiri S; Kiertiburanakul S; Sutthent R; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Horsakulthai M; Chasombat S; Ruxrungtham K;
    J Int Assoc Physicians AIDS Care (Chic); 2006 Dec; 5(4):152-6. PubMed ID: 17101807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The K65R mutation in HIV-1 reverse transcriptase.
    Winston A; Stebbing J
    J HIV Ther; 2004 May; 9(2):25-7. PubMed ID: 15238872
    [No Abstract]   [Full Text] [Related]  

  • 14. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of resistance testing.
    Stebbing J; Gazzard BG
    J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 17. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay.
    Liuzzi G; Chirianni A; Zaccarelli M; Zinzi D; Esposito V; Guadagnino V; Antinori A; Piazza M
    In Vivo; 2004; 18(4):509-12. PubMed ID: 15369193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.